T-DM1 has been approved by European Medicines Agency (EMA) and FDA as a single treatment agent for patients with HER2+ metastatic BC progressed and adjuvant treatment of patients with HER2+ early BC who have the residual invasive disease both after therapy with Trastuzumab and chemotherapy [11,14,67]. Here, ERBB2 is linked to breast cancer.